



July 26, 2023

BSE Limited
Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E), Mumbai - 400 051

Scrip Code: **543271**

Trading Symbol: **JUBLINGREA**

Dear Sirs,

In terms of Regulation 33 and 52(4) read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations"), we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2023 were approved by the Board of Directors of the Company at its meeting held today at 11:15 am and concluded at 2:30 pm.

Pursuant to applicable provisions of the Listing Regulations, we enclose the following:

1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2023;
2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter.

We request you to take the same on record.

Thanking you

Yours faithfully,

For Jubilant Ingrevia Limited

Deepanjali Gulati
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Ingrevia Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubilantingrevia.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223
Uttar Pradesh, India
CIN : L24299UP2019PLC122657

Walker ChandioK & Co LLP

Plot No. 19A, 2nd floor,
Sector - 16A,
Noida - 201 301
Uttar Pradesh, India

T +91 120 485 5999

F +91 120 485 5902

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Company') for the quarter ended 30 June 2023, being submitted by the Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended).
2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended). Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiook & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani
Partner
Membership No. 517440

UDIN: 23517440BGZUCS1673

Place: Noida
Date: 26 July 2023



Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubl.com, Tel: +91-5924-267437

Statement of Standalone Unaudited Financial Results for the Quarter ended 30 June 2023

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2023	2023	2022	2023
1	Revenue from operations				
	a) Sales/Income from operations	102436	104653	115123	452839
	b) Other operating Income	636	1448	643	3118
	Total revenue from operations	103072	106101	115766	455957
2	Other income	961	836	947	3103
3	Total income (1+2)	104033	106937	116713	459060
4	Expenses				
	a) Cost of materials consumed	57891	54458	68364	254776
	b) Purchases of stock-in-trade	1335	3806	2259	11343
	c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(5563)	2097	(6918)	(12437)
	d) Employee benefits expense	8365	7626	7340	30588
	e) Finance costs	1528	983	799	3824
	f) Depreciation and amortisation expense	3169	2923	3077	11974
	g) Other expenses:				
	- Power and fuel expense	16239	15300	19375	71988
	- Others	13391	14099	11200	50246
	Total expenses	96355	101292	105496	422302
5	Profit before tax (3-4)	7678	5645	11217	36758
6	Tax expense				
	- Current tax	1396	1002	2283	6405
	- Deferred tax charge	800	776	1290	5012
7	Net profit for the period/year (5-6)	5482	3867	7644	25341
8	Other comprehensive income (OCI)				
	i) a) Items that will not be reclassified to profit or loss	(36)	57	(43)	(144)
	b) Income tax relating to items that will not be reclassified to profit or loss	13	(20)	15	50
	ii) a) Items that will be reclassified to profit or loss	-	-	-	-
	b) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
9	Total comprehensive income for the period/year (7+8)	5459	3904	7616	25247
10	Earnings per share of ₹ 1 each (not annualised for the quarters)				
	Basic (₹)	3.44	2.43	4.80	15.91
	Diluted (₹)	3.44	2.43	4.80	15.91
11	Paid-up equity share capital (face value per share ₹ 1)	1593	1593	1593	1593
12	Reserves excluding revaluation reserves (other equity)				214264
	See accompanying notes to the Standalone Unaudited Financial Results				



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited

Note 1: Standalone Unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter ended 30 June 2023

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2023	2023	2022	2023
1	Segment revenue				
	a. Speciality Chemicals	44614	50425	45630	195947
	b. Nutrition & Health Solutions	17620	12921	18996	52328
	c. Chemical Intermediates	48589	47625	61568	230250
	Total	110823	110971	126194	478525
	Less : Inter segment revenue	7751	4870	10428	22568
	Total revenue from operations	103072	106101	115766	455957
	a. Speciality Chemicals	37083	45799	37864	177665
	b. Nutrition & Health Solutions	17620	12921	18996	52328
	c. Chemical Intermediates	48369	47381	58906	225964
	Total	103072	106101	115766	455957
2	Segment results (profit before tax and interest from each segment)				
	a. Speciality Chemicals	3601	3719	4525	20260
	b. Nutrition & Health Solutions	1667	(518)	2242	2240
	c. Chemical Intermediates	4818	4289	6129	21408
	Total	10086	7490	12896	43908
	Less: i. Interest (finance costs)	1528	983	799	3824
	ii. Un-allocable expenditure (net of un-allocable income)	880	862	880	3326
	Profit before tax	7678	5645	11217	36758
3	Segment assets				
	a. Speciality Chemicals	233124	220128	196372	220128
	b. Nutrition & Health Solutions	39375	34954	41287	34954
	c. Chemical Intermediates	134069	126805	140778	126805
	d. Unallocable corporate assets	26626	23952	21239	23952
	Total segment assets	433194	405839	399676	405839
4	Segment liabilities				
	a. Speciality Chemicals	46128	52143	46690	52143
	b. Nutrition & Health Solutions	12017	12635	16501	12635
	c. Chemical Intermediates	62544	45559	64897	45559
	d. Unallocable corporate liabilities	91140	79645	65638	79645
	Total segment liabilities	211829	189982	193726	189982



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited

Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Standalone)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2023	2023	2022	2023
1	Debt service coverage ratio (in times)# <i>Definition: EBITDA/(finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts)</i> <i>(EBITDA: Profit before tax + depreciation and amortisation expense + finance costs)</i>	8.10	9.72	18.89	13.74
2	Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i>	8.10	9.72	18.89	13.74
3	Bad debts to account receivable ratio (%)# <i>Definition: Bad debts/average of opening and closing trade receivables</i> <i>(Bad debts: Impairment balance as per statements of profit and loss)</i>	0.03%	0.05%	0.06%	0.05%
4	Debtors turnover (in times)# <i>Definition: Revenue from operations/average of opening and closing trade receivables</i>	2.10	2.05	1.95	8.43
5	Inventory turnover (in times)# <i>Definition: Cost of goods sold/average of opening and closing inventories</i>	0.56	0.69	0.73	3.09
6	Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> <i>(Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses)</i> <i>(Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress)</i>	8.00%	5.46%	9.56%	8.22%
7	Net profit margin (%) <i>Definition: Net profit/total income</i>	5.27%	3.62%	6.55%	5.52%
8	Net worth (In ₹ Lakhs) <i>(Net worth: Equity share capital + other equity)</i>	221365	215857	205950	215857
9	Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> <i>(Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances)</i>	0.31	0.26	0.22	0.26
10	Current ratio (in times) <i>Definition: Current assets/current liabilities</i>	1.06	1.26	1.26	1.26
11	Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> <i>(Long term debt: Long term borrowings (gross of transaction costs)</i> <i>(working capital: Current assets - current liabilities)</i>	1.52	1.03	0.52	1.03
12	Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i>	0.79	0.67	0.76	0.67
13	Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> <i>(Total debts: Long term borrowings (gross of transaction costs) + short term borrowings)</i>	0.16	0.15	0.12	0.15

not annualised for the quarters

(This space has been intentionally left blank)



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Notes to standalone unaudited financial results (cont'd):

3. During the quarter ended 30 June 2023, the Company has further invested an amount of ₹ 4000 lakhs in 0.50% optionally convertible debenture of its wholly owned subsidiary Jubilant Agro Sciences Limited (formerly known as Jubilant Crop Protection Limited)
4. The Company does not have any outstanding unsecured listed commercial papers as at 30 June 2023. Subsequent to the quarter-end, the Company has issued unsecured listed commercial papers (CPs) of ₹ 40000 lakhs which are listed on the National Stock Exchange of India. Details of CPs are as follows:

ISIN No.	Issue date	Due date of repayment	Redemption amount
INE0BY014177	12 July 2023	25 August 2023	₹ 10000 lakhs
INE0BY014185	14 July 2023	5 September 2023	₹ 17500 lakhs
INE0BY014193	25 July 2023	18 September 2023	₹ 12500 lakhs

5. During the quarter ended 30 June 2023, the Company has commissioned new 'Acetic Anhydride' plant at Bharuch, Gujarat
6. During the quarter ended 30 June 2023, the Company has granted 36438 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Holding Company.
7. The figures for the quarter ended 31 March 2023, as reported in the standalone financial results, are the balancing figures between the audited figures for the year ended 31 March 2023 and the published year to date figures for 31 December 2022, which were subjected to limited review by the statutory auditors
8. The above standalone unaudited financial results were subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 26 July 2023. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on standalone financial results, visit investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited



Rajesh Kumar Srivastava
CEO & Managing Director

Place : Noida
Date : 26 July 2023



SIGNED FOR
IDENTIFICATION
PURPOSES



Walker ChandioK & Co LLP

Plot No. 19A, 2nd floor,
Sector - 16A,
Noida - 201 301
Uttar Pradesh, India

T +91 120 485 5999
F +91 120 485 5902

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Ingrevia Limited

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Jubilant Ingrevia Limited ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), and its associates (refer Annexure 1 for the list of subsidiaries and associates included in the Statement) for the quarter ended 30 June 2023, being submitted by the Holding Company pursuant to the requirements of Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations') read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended).
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended). Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the SEBI under Regulation 33 (8) of the Listing Regulation, to the extent applicable.



Chartered Accountants

Offices in Ahmedabad, Bengaluru, Chandigarh, Chennai, Dehradun, Gurugram, Hyderabad, Kolkata, Mumbai, New Delhi, Noida and Pune

Walker ChandioK & Co LLP is registered with limited liability with identification number AAC-2085 and has its registered office at L-41, Connaught Circus, Outer Circle, New Delhi, 110001, India

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

4. Based on our review conducted and procedures performed as stated in paragraph 3 above and upon consideration of the review report of the other auditor referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations read with SEBI Circular SEBI/HO/DDHS/P/CIR/2021/613 dated 10 August 2021 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The Statement also includes the Group's share of net loss after tax of ₹ 8.04 lakhs and total comprehensive loss of ₹ 8.04 lakhs for the quarter ended on 30 June 2023, as considered in the Statement, in respect of an associate, whose interim financial information have not been reviewed by us. This interim financial information has been reviewed by other auditor whose review report has been furnished to us by the management, and our conclusion in so far as it relates to the amounts and disclosures included in respect of this associate is based solely on the review report of such other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter with respect to our reliance on the work done by and the report of the other auditor.

For Walker Chandio & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

Madhu Sudan

Madhu Sudan Malpani
Partner
Membership No. 517440



UDIN: 23517440BGZUCR2819

Place: Noida
Date: 26 July 2023

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of Jubilant Ingrevia Limited pursuant to the Regulation 33 and Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) (cont'd)

Annexure 1

List of entities included in the Statement:

S. No.	Name	Relationship with the Holding Company
1	Jubilant Infrastructure Limited	Subsidiary
2	Jubilant Agro Sciences Limited	Subsidiary
3	Jubilant Life Sciences (USA) Inc.	Subsidiary
4	Jubilant Life Sciences NV	Subsidiary
5	Jubilant Life Sciences International Pte. Limited	Subsidiary
6	Jubilant Life Sciences (Shanghai) Limited	Subsidiary
7	Jubilant Ingrevia Employee Welfare Trust	Subsidiary
8	Mister Veg Foods Private Limited	Associate
9	AMP Energy Green Fifteen Private Limited	Associate



Jubilant Ingrevia Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24299UP2019PLC122657

Website: www.jubilantingrevia.com, Email: investors.ingrevia@jubil.com, Tel: +91-5924-267437

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30 June 2023

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2023	2023	2022	2023
1	Revenue from operations				
	a) Sales/Income from operations	106866	112948	115939	474048
	b) Other operating income	636	1550	643	3221
	Total revenue from operations	107502	114498	116582	477269
2	Other income	850	900	1008	3337
3	Total income (1+2)	108352	115398	117590	480606
4	Expenses				
	a) Cost of materials consumed	57891	54486	68357	254776
	b) Purchases of stock-in-trade	2090	5447	3761	16155
	c) Changes in inventories of finished goods, stock-in-trade and work-in progress	(4959)	4855	(11200)	(12774)
	d) Employee benefits expense	9344	8602	8215	34348
	e) Finance costs	1146	570	409	2158
	f) Depreciation and amortisation expense	3230	2984	3136	12218
	g) Other expenses:				
	- Power and fuel expense	15939	15030	19176	70911
	- Others	15532	15873	14185	59139
	Total expenses	100213	107847	106039	436931
5	Profit before share of (loss)/profit of an associate (3-4)	8139	7551	11551	43675
6	Share of (loss)/profit of an associate	(8)	1	-*	(4)
7	Profit before tax (5+6)	8131	7552	11551	43671
8	Tax expense				
	- Current tax	1676	1150	2487	7023
	- Deferred tax charge	696	1171	1126	5898
9	Net profit for the period/year (7-8)	5759	5231	7938	30750
10	Other comprehensive income (OCI)				
	i) a) Items that will not be reclassified to profit or loss	33	67	(90)	(166)
	b) Income tax relating to items that will not be reclassified to profit or loss	6	(43)	15	27
	ii) a) Items that will be reclassified to profit or loss	(68)	371	(329)	323
	b) Income tax relating to items that will be reclassified to profit or loss	14	(85)	233	56
11	Total comprehensive Income for the period/year (9+10)	5744	5541	7767	30990
	Net profit attributable to:				
	Owners of the Company	5759	5231	7938	30750
	Non-controlling interests	-	-	-	-
	Other comprehensive income attributable to:				
	Owners of the Company	(15)	310	(171)	240
	Non-controlling interests	-	-	-	-
	Total comprehensive income attributable to:				
	Owners of the Company	5744	5541	7767	30990
	Non-controlling interests	-	-	-	-
12	Earnings per share of ₹ 1 each (not annualised for the quarters)				
	Basic (₹)	3.63	3.29	4.99	19.34
	Diluted (₹)	3.63	3.29	4.99	19.33
13	Paid-up equity share capital (face value per share ₹ 1)	1580	1590	1590	1590
14	Reserves excluding revaluation reserves (other equity)				265033
	See accompanying notes to the Consolidated Unaudited Financial Results				

* rounded off to Nil



**SIGNED FOR
IDENTIFICATION
PURPOSES**



Jubilant Ingrevia Limited

Note 1: Consolidated unaudited Segment wise Revenue, Results, Assets and Liabilities for the Quarter ended 30 June 2023

(₹ in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2023	2023	2022	2023
1	Segment revenue				
	a. Speciality Chemicals	43908	51427	46012	198118
	b. Nutrition & Health Solutions	20227	15523	15022	55117
	c. Chemical Intermediates	51118	52418	65976	246602
	Total	115253	119368	127010	499837
	Less : Inter segment revenue	7751	4870	10428	22568
	Total revenue from operations	107502	114498	116582	477269
	a. Speciality Chemicals	36377	46801	38246	179836
	b. Nutrition & Health Solutions	20227	15523	15022	55117
	c. Chemical Intermediates	50898	52174	63314	242316
	Total	107502	114498	116582	477269
2	Segment results (profit before tax and interest from each segment)				
	a. Speciality Chemicals	3871	3804	4706	21519
	b. Nutrition & Health Solutions	1356	158	1551	3264
	c. Chemical Intermediates	4944	4987	6576	24366
	Total	10171	8949	12833	49149
	Less: i. Interest (finance costs)	1146	570	409	2158
	ii. Un-allocable expenditure (net of un-allocable income)	894	827	873	3320
	Profit before tax	8131	7552	11551	43671
3	Segment assets				
	a. Speciality Chemicals	250505	230381	201053	230381
	b. Nutrition & Health Solutions	50610	44553	53738	44553
	c. Chemical Intermediates	140304	137256	150591	137256
	d. Unallocable corporate assets	11635	13698	11976	13698
	Total segment assets	453054	425888	417358	425888
4	Segment liabilities				
	a. Speciality Chemicals	47324	52460	45877	52460
	b. Nutrition & Health Solutions	9162	8108	13930	8108
	c. Chemical Intermediates	52350	39806	61269	39806
	d. Unallocable corporate liabilities	76091	58891	45174	58891
	Total segment liabilities	184927	159265	166250	159265



SIGNED FOR
IDENTIFICATION
PURPOSES



Jubilant Ingrevia Limited

Note 2: Additional disclosure as per Regulation 52 (4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (Consolidated)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2023	2023	2022	2023
1	Debt service coverage ratio (in times)# <i>Definition: EBITDA/finance costs + scheduled principal repayments (excluding prepayments) during the period for long-term debts</i> <i>(EBITDA: Profit before tax + depreciation and amortisation expense + finance costs)</i>	10.91	19.50	36.93	26.90
2	Interest service coverage ratio (in times) <i>Definition: EBITDA/finance costs</i>	10.91	19.50	36.93	26.90
3	Bad debts to account receivable ratio (%)# <i>Definition: Bad debts/average of opening and closing trade receivables</i> <i>(Bad debts: Impairment balance as per statements of profit and loss)</i>	0.03%	0.05%	0.06%	0.09%
4	Debtors turnover (in times)# <i>Definition: Revenue from operations/average of opening and closing trade receivables</i>	2.21	2.20	2.02	8.74
5	Inventory turnover (in times)# <i>Definition: Cost of goods sold/average of opening and closing inventories</i>	0.50	0.62	0.59	2.65
6	Operating margin (%) <i>Definition: Operating profit/revenue from operations</i> <i>(Operating profit: Revenue from operations - cost of goods sold - employee benefits expense - depreciation and amortisation expense - other expenses)</i> <i>(Cost of goods sold: Cost of materials consumed + purchases of stock-in-trade + changes in inventories of finished goods, stock-in-trade and work-in-progress)</i>	7.85%	6.31%	9.39%	8.90%
7	Net profit margin (%) <i>Definition: Net profit/total income</i>	5.31%	4.53%	6.75%	6.40%
8	Net worth (In ₹ Lakhs) <i>(Net worth: Equity share capital + other equity)</i>	268127	266623	251108	266623
9	Debt equity ratio (in times) <i>Definition: Net debts/net worth</i> <i>(Net debts: Long term borrowings (gross of transaction costs) + short term borrowings - cash and cash equivalents - other bank balances)</i>	0.18	0.12	0.09	0.12
10	Current ratio (in times) <i>Definition: Current assets/current liabilities</i>	1.36	1.54	1.45	1.54
11	Long term debt to working capital (in times) <i>Definition: Long term debt/working capital</i> <i>(Long term debt: Long term borrowings (gross of transaction costs))</i> <i>(Working capital: Current assets - current liabilities)</i>	0.29	0.23	-	0.23
12	Current liability ratio (in times) <i>Definition: Current liabilities/total liabilities</i>	0.77	0.74	0.87	0.74
13	Total debts to total assets (in times) <i>Definition: Total debts/total assets</i> <i>(Total debts: Long term borrowings (gross of transaction costs) + short term borrowings)</i>	0.12	0.09	0.07	0.09

not annualised for the quarters

(This space has been intentionally left blank)



SIGNED FOR
IDENTIFICATION
PURPOSES



Notes to consolidated unaudited financial results (cont'd):

3. The Holding Company does not have any outstanding unsecured listed commercial papers as at 30 June 2023. Subsequent to the quarter-end, the Company has issued unsecured listed commercial papers (CPs) of ₹ 40000 lakhs which are listed on the National Stock Exchange of India. Details of CPs are as follows:

ISIN No.	Issue date	Due date of repayment	Redemption amount
INE0BY014177	12 July 2023	25 August 2023	₹ 10000 lakhs
INE0BY014185	14 July 2023	5 September 2023	₹ 17500 lakhs
INE0BY014193	25 July 2023	18 September 2023	₹ 12500 lakhs

4. During the quarter ended 30 June 2023, the Holding Company has commissioned new 'Acetic Anhydride' plant at Bharuch, Gujarat.
5. During the quarter ended 30 June 2023, the Holding Company has granted 36438 stock options to the eligible employees as determined by the Nomination, Remuneration and Compensation Committee of the Holding Company.
6. The figures for the quarter ended 31 March 2023, as reported in the consolidated financial results, are the balancing figures between the audited figures for the year ended 31 March 2023 and the published year to date figures for 31 December 2022, which were subjected to limited review by the statutory auditors.
7. The above consolidated unaudited financial results were subjected to limited review by the Statutory Auditors of the Holding Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 26 July 2023. The review report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited. For more details on consolidated financial results, visit Investors section of our website at www.jubilantingrevia.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Ingrevia Limited



Rajesh Kumar Srivastava
CEO & Managing Director

Place : Noida
Date : 26 July 2023



**SIGNED FOR
IDENTIFICATION
PURPOSES**

